ASH 2023 | DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the DeRIVE trial (NCT03942224), a randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId) vs daratumumab, bortezomib, and dexamethasone (DVd) followed by DId, in newly diagnosed patients with multiple myeloma (MM). Dr Lonial discusses the differences in patient outcomes between the two study arms. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
DeRIVE was a study in which we were trying to understand where is ixazomib versus bortezomib could fit in the first four cycles of initial therapy. And part of what we were trying to understand was speed of response, and what we determined was that, for patients, the speed of response was quicker for the subcutaneous bortezomib than it was for the ixazomib. After four cycles of therapy, they then switched to ixazomib for all groups, and what we showed was that over time, particularly up to cycle eight, the responses continued to deepen...
DeRIVE was a study in which we were trying to understand where is ixazomib versus bortezomib could fit in the first four cycles of initial therapy. And part of what we were trying to understand was speed of response, and what we determined was that, for patients, the speed of response was quicker for the subcutaneous bortezomib than it was for the ixazomib. After four cycles of therapy, they then switched to ixazomib for all groups, and what we showed was that over time, particularly up to cycle eight, the responses continued to deepen. Several patients then went on to transplant as consolidation afterwards, and then received ixazomib and daratumumab as maintenance therapy. And what we found was that this treatment approach really did result in a very high percentage of patients achieving complete remission, many patients achieving MRD-negativity, and more importantly, this was very well tolerated with a defined period of treatment.
Read more...
Disclosures
Research Funding: Novartis, Janssen
Consultancy: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc.
Advisory Committee: TG Therapeutics Inc:
Board of Directors with Stock: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Contracted Research: Janssen
